Prostate Cancer new approaches and treatments from the quality of life perspective
14th International Conference on Cancer and Cancer Therapy
December 05-06, 2019 | Dubai, UAE
Haluk Kulaksizoglu
A A Medical Center Dubai, UAE
Scientific Tracks Abstracts : J Med Oncl Ther
Abstract:
Aim: Over the last 5 years the understanding of prostate cancer
behavior, improvement in technologies relating to diagnostic
techniques, better surgical and radiotherapy methods and
new emerging drugs have pushed us to changing our insight
to prostate cancer. The aim in this talk is to give an overview
of new clinical applications and techniques that improve lifespan
as well as the quality of life in both the patients and their
spouses.
Method: The presentation is based on relevant scientific data
available relating to changes that occurred over the last few
years in diagnosis, treatment and follow-up of prostate cancer
patients.
Findings: When and how to screen prostate cancer patients
has been a major concern among communities, health care
providers and the related medical societies’ guidelines.
Strategies resulting in overdiagnosis versus un-detection of
malignant tumors are based on the fact that prostate cancer
may not be actually one type of disease but a large spectrum.
Use of imaging has evolved our thinking of screening.
Multiparametric Prostate MRI has given us 2 unique leverage:
(i) we can detect if the PSA elevation is more predictive
of cancer or other pathologies of the prostate gland Pi-
RADS Scoring System (ii) we can do more accurate biopsies
to identify cancer coupling MRI images with transrectal
ultrasound images during biopsy in fusion biopsy systems.
Biomarker studies to improve PSA sensitivity and specifity is
still a work-in-progress. Avoiding unnecessary biopsies and
having an imagery follow-up of suspicious or cancerous cells
increase the quality of life. It is safer for patients to undergo
‘active surveillance’with new advances. Once at a treatment
phase, robotic surgery is of course the gold standard to
improve patients recovery time, time to catheter removal
and post-surgery erection quality and recovery. Previous
guidelines dictated that patients with tumors limited to the
capsule can only have definitive treatments. New data show
that even in patients with positive lymph node limited to
iliac nodes and T3 patients with no fixation to the rectum are
candidates for surgical tumor removal. Decreasing the tumor
burden with a minimally invasive surgery has been proven
to increase survival. Additional excelling of radiotherapy
techniques also increased in patients with high stage surgeries
as well as those who are not candidates for surgical procedures.
Local radiotherapy results are as promising as surgeries. High
intensity focused ultrasound, cryotherapy options are also
present for patients. Medical therapies have also improved
to include new hormonal approaches, immune therapies
and more targeted anti-neoplastic medical therapies. While
improving treatment results, many of the new regimens are
also aiming at preventing or decreasing many cardiac, bonerelated
and sexual dysfunctions. Recovery protocols for erectile
dysfunction are also more effective. Adjunctive therapies such
as low-intensity shockwave therapies, PRP to oral therapies are
expected to give better recovery in a shorter period of time. For
scientific proof of adjunct therapies we need to wait for longterm
results to appear.
Conclusion: Being one of the major cancers in male, prostate
cancer diagnosis, treatments and follow-up protocols have
been changing rapidly over the last few years. Due to better
diagnostic tools, better surgical technologies and better
innovations in both pharmacotherapy, medical device and
radiotherapy options provide prolonged survival, better
survival-free follow-up and improved quality of life.
Biography:
Haluk Kulaksizoglu is an experienced Professor of Urology with a demonstrated history of working in the hospital & health care industry. He is skilled in Prostate Diseases, Andrology, Urodynamic, Medical Devices, Kidney Stones, and Kidney Cancer. Strong healthcare services professional with a doctorate focused in medicine from Cerrahpasa Medical School.
E-mail: hlkkulaksizoglu@gmail.com
PDF HTML